Novo Nordisk Plunges After Ozempic Pill Fails Alzheimer's Trials - Shares Suffer Worst Year Ever Shares of Novo Nordisk in Copenhagen plunged the most in nearly four months after top-line results from a two-year analysis of the evoke and evoke+ Phase 3 trials, a pill version of Ozempic, showed the t......